Politics Nicholas Florko STAT Plus: FDA’s vaccines and biologics chief talks Covid-19, 2022 priorities, and getting back to gene, cell therapy review
Biotech Adam Feuerstein STAT Plus: Patients with rare blood disorder benefit from Bluebird gene therapy while denied access in Europe
Pharmalot Ed Silverman STAT Plus: What’s in a name? Spark Therapeutics sues Bluebird Bio over the use of the word ‘spark’
Biotech Jonathan Saltzman — Boston Globe STAT Plus: Affinia Therapeutics raises $110 million for gene therapy treatments
Biotech Adam Feuerstein STAT Plus: Bluebird’s withdrawal of therapy from Germany could chill talks over gene therapy prices across Europe
Biotech Adam Feuerstein STAT Plus: Uniqure investigation clears hemophilia B gene therapy as cause of patient’s liver cancer
Biotech Adam Feuerstein STAT Plus: Bluebird suspends studies of sickle cell gene therapy following cancer diagnoses in two more treated patients
Biotech Adam Feuerstein STAT Plus: Sarepta gene therapy for Duchenne muscular dystrophy stumbles with failed study outcome
Biotech Adam Feuerstein STAT Plus: New rare disease gene therapy startup recruits former Sarepta executive as CEO
Biotech Damian Garde STAT Plus: In a shocking decision, FDA rejects BioMarin’s gene therapy for hemophilia
Health Elizabeth Cooney STAT Plus: Recapping ASCO 2020, talking cancer therapy combinations, and looking to the future
Biotech Matthew Herper STAT Plus: Pfizer says efficacy of its Duchenne gene therapy outweighs side effects
In the Lab Rebecca Robbins STAT Plus: Gene therapy pioneer says the field is behind — and that delivery technology is ‘embarrassing’
First Opinion Jeremy Schafer Should employers take a chance on little-known Embarc to pay for gene therapy?
Pharmalot Ed Silverman STAT Plus: Novartis unit says FDA wasn’t told of data manipulation sooner because it was ‘highly complex’
Biotech Jonathan Saltzman — Boston Globe STAT Plus: The world’s most expensive medicine could save toddlers’ lives. But getting it is complicated
Biotech Adam Feuerstein STAT Plus: Bluebird’s gene therapy for a rare blood disease will cost $1.8 million. Cue the pricing debate
Biotech Adam Feuerstein and Matthew Herper STAT Plus: Biomarin to seek approval for hemophilia gene therapy, but durability questions persist
Pharma Adam Feuerstein STAT Plus: At $2.1 million, newly approved Novartis gene therapy will be world’s most expensive drug
Biotech Jonathan Saltzman — Boston Globe STAT Plus: Novartis CEO coy about pricing its gene therapy for spinal muscular atrophy
Biotech Adam Feuerstein STAT Plus: Tocagen continues a brain cancer gene therapy clinical trial. Investors fear the worst
Biotech Adam Feuerstein STAT Plus: BioMarin’s hemophilia gene therapy faces a crucial durability test. Here are 9 things to know
Biotech Adam Feuerstein STAT Plus: With positive early results, Sarepta appears to have a second gene therapy with potential
Biotech Matthew Herper STAT Plus: Solid Biosciences to soldier on as initial muscular dystrophy gene therapy results disappoint
Biotech Adam Feuerstein STAT Plus: With new data, a biotech tries to relieve doubts about the durability of its gene therapy for Fabry disease
Adam's Take Adam Feuerstein STAT Plus: Misfortune strikes a Bluebird patient, highlighting the safety risks involved with gene therapy